1 research outputs found
Convalescent plasma for persisting Covidâ19 following therapeutic lymphocyte depletion: a report of rapid recovery
International audienceWe read with deep interest the report by Tepasse et al .1 concerning two cases of persisting viraemia in coronavirus disease 2019 (COVIDâ19) with fatal outcome. Whilst severe acute respiratory syndrome coronavirusâ2 (SARSâCoVâ2) infection in the early stages of infection has been well described, less is known about the development of antibodies to SARSâCoVâ2, clearance of RNA shedding and clinical outcome of COVIDâ19. In addition, the impact of immunosuppressive treatments on disease severity is not yet established, but several reports suggest a more prolonged disease in patients under rituximab, a Bâcell depleting drug.2-4 Here we report a case of persisting COVIDâ19, following combined treatment with rituximab and bendamustine for lymphoma, which immediately recovered after convalescent plasma transfusion. We think that this case raises promising perspectives for immunocompromised patients with persisting COVIDâ19